Pair page
GW-0742 with SLU-PP-332
Mechanism-tag overlap and published literature for GW-0742 and SLU-PP-332, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ppar-agonist
err-pan-agonist-exercise-mimetic
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying GW-0742 and SLU-PP-332 have published these mechanism-level observations. Not a co-administration recommendation.
SLU-PP-332 is an estrogen-related-receptor (ERR) pan-agonist with overlapping exercise-mimetic transcriptional effects via a parallel nuclear-receptor pathway. Combined PPARδ + ERR activation is explored in preclinical exercise-mimetic studies but has no human evidence. Stacking compounds oxidative-metabolism adaptations and compounds safety uncertainty.
Quick facts
GW-0742
SLU-PP-332
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2008 | GW-0742 | Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F. Activation of pe… PMID 18285555 | human trial, Phase 2 |
| 2005 | GW-0742 | Graham TL, Mookherjee C, Suckling KE, Palmer CN, Patel L. The PPARδ agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis. 2005;181(1):29-37. PMID: 15939051. (GW-0742 atherosclerosis data.) PMID 15939051 | preclinical, in vivo |
| 2005 | GW-0742 | Planavila A, Rodríguez-Calvo R, Jové M, Michalik L, Wahli W, Laguna JC, Vázquez-Carrera M. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;65(4):832-841. PMID: 15721862. (GW-0742 cardiac-h… PMID 15721862 | preclinical, in vivo |
| 2003 | GW-0742 | Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr, Sternbach DD. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta) — synthesis… PMID 12699745 | mechanism / discovery |
| 2012 | GW-0742 | Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012;12(3):181-195. PMID: 22318237. (Comprehensive review of PPARs and cancer risk — the central safety-framing source for the class.) PMID 22318237 | review |
| 2026 | GW-0742 | WADA. 2026 World Anti-Doping Code Prohibited List. Section S4.5 — Metabolic Modulators. World Anti-Doping Agency. Effective January 1, 2026. | regulatory / registry |
| 2018 | GW-0742 | Palomer X, Barroso E, Pizarro-Delgado J, Peña L, Botteri G, Zarei M, Aguilar D, Montori-Grau M, Vázquez-Carrera M. PPARβ/δ: a key therapeutic target in metabolic disorders. Int J Mol Sci. 2018;19(3):913. PMID: 29558390. PMID 29558390 | research article |
| 2016 | GW-0742 | Tan NS, Vázquez-Carrera M, Montagner A, Sng MK, Guillou H, Wahli W. Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ. Prog Lipid Res. 2016;64:98-122. PMID: 27665713. PMID 27665713 | research article |
| 2010 | GW-0742 | Wagner KD, Wagner N. Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther. 2010;125(3):423-435. PMID: 20026354. PMID 20026354 | research article |
| 2008 | GW-0742 | Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARδ agonists are exercise mimetics. Cell. 2008;134(3):405-415. PMID: 18674809. PMID 18674809 | research article |
| 2007 | GW-0742 | Hollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN, Willson TM, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta/delta (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis. 2007;28(12):2641-26… PMID 17693662 | research article |
| 2006 | GW-0742 | Barish GD, Narkar VA, Evans RM. PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006;116(3):590-597. PMID: 16511591. PMID 16511591 | research article |
| 2020 | SLU-PP-332 | Tripathi M, Yen PM, Singh BK. Estrogen-related receptor alpha: an under-appreciated potential target for the treatment of metabolic diseases. Int J Mol Sci. 2020;21(5):1645. PMID: 32121253. PMID 32121253 | human study |
| 2025 | SLU-PP-332 | World Anti-Doping Agency. 2025 WADA Prohibited List. Section S4: Hormone and metabolic modulators. WADA, 2025. | regulatory / registry |
| 2024 | SLU-PP-332 | Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024;388(2):232-240. PMID: 37739806. PMID 37739806 | research article |
| 2017 | SLU-PP-332 | Fan W, Evans R. Exercise Mimetics: Impact on Health and Performance. Cell Metab. 2017;25(2):242-247. PMID: 27889389. PMID 27889389 | research article |
| 2017 | SLU-PP-332 | Misra J, Kim DK, Choi HS. ERRγ: a Junior Orphan with a Senior Role in Metabolism. Trends Endocrinol Metab. 2017;28(4):261-272. PMID: 28209382. PMID 28209382 | research article |
| 2015 | SLU-PP-332 | Huss JM, Garbacz WG, Xie W. Constitutive activities of estrogen-related receptors: Transcriptional regulation of metabolism by the ERR pathways in health and disease. Biochim Biophys Acta. 2015;1852(9):1912-1927. PMID: 26115970. PMID 26115970 | research article |
| 2013 | SLU-PP-332 | Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, Lundasen T, Hughes T, Kojetin DJ. Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev. 2013;65(2):710-778. PMID: 23457206. PMID 23457206 | research article |
| 2011 | SLU-PP-332 | Narkar VA, Fan W, Downes M, Yu RT, Jonker JW, Alaynick WA, Banayo E, Karunasiri MS, Lorca S, Evans RM. Exercise and PGC-1α-independent synchronization of type I muscle metabolism and vasculature by ERRγ. Cell Metab. 2011;13(3):283-293. PMID: 21356518. PMID 21356518 | research article |
| 2010 | SLU-PP-332 | Rangwala SM, Wang X, Calvo JA, Lindsley L, Zhang Y, Deyneko G, Beaulieu V, Gao J, Turner G, Markovits J. Estrogen-related receptor gamma is a key regulator of muscle mitochondrial activity and oxidative capacity. J Biol Chem. 2010;285(29):22619-22629. PMID: 20418374. PMID 20418374 | research article |
| 2008 | SLU-PP-332 | Giguère V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev. 2008;29(6):677-696. PMID: 18664618. PMID 18664618 | research article |
| 2008 | SLU-PP-332 | Villena JA, Kralli A. ERRalpha: a metabolic function for the oldest orphan. Trends Endocrinol Metab. 2008;19(8):269-276. PMID: 18778951. PMID 18778951 | research article |
| 2007 | SLU-PP-332 | Villena JA, Hock MB, Chang WY, Barcas JE, Giguère V, Kralli A. Orphan nuclear receptor estrogen-related receptor alpha is essential for adaptive thermogenesis. Proc Natl Acad Sci USA. 2007;104(4):1418-1423. PMID: 17229846. PMID 17229846 | research article |
Related pair pages
More research context
Frequently asked
Have GW-0742 and SLU-PP-332 been studied together?
Researchers have published mechanistic-level co-administration discussion of GW-0742 and SLU-PP-332. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do GW-0742 and SLU-PP-332 share?
GW-0742 and SLU-PP-332 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of GW-0742 and SLU-PP-332?
GW-0742: Never entered clinical trials. SLU-PP-332: Not approved (no IND). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on GW-0742 and SLU-PP-332?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the GW-0742 profile and the SLU-PP-332 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026